The following murine cancer models are available at Bienta:

Syngeneic tumor

mouse models are established with murine cancer cell lines in immuno-competent mice. Syngeneic mouse models are excellent for studying new antitumor therapeutic agents in the presence of a functional immune system. C3H, C57Bl/6J, or C57Bl/6N mice strains are used to establish the syngeneic model.

Xenograft tumor

models are set up with human cancer cells inoculated in athymic (nude) or severe combined immune deficient (SCID) mice. The model can be delivered as a subcutaneous or orthotopic xenograft tumor. Xenograft models allow assessing the efficacy of a drug or therapy specifically against human cancer cells. CD1-Foxn1nu and SCID/beige are in-house, and other mouse strains are on-demand.

Service details

A standard study design includes 7 days of acclimatization period, 5-15 days of subcutaneous tumor growth, a study-specific treatment period, and post-treatment observation. Tumor size measurements are usually initiated on day 3-5 post-cancer cells inoculation and monitored daily using a caliper. A study design includes a minimum of 2 groups of mice (tumor-bearing vehicle-treated, and tumor-bearing compound-treated group), 10-15 mice per group. Drug administration can be performed either via invasive (by IV, IP, SC, and IM routes), or noninvasive (PO, IN, or with food/drink) routes. Other specific types of treatment are also possible, for example, photodynamic therapy (PDT) using a wide range of irradiation wavelengths.

Lewis Lung Carcinoma (LLC) growth dynamics in young male C57Bl/6j mice treated with anticancer compounds A, B, and C. 1×10*6 cells in 100 μl (50 μl DMEM+50 μl Matrigel)

Tumor treatment procedures

include invasive (by IV, IP, SC, and PO routes), noninvasive (with food) routes of drug administration, as well photodynamic therapy (PDT) using a wide range of irradiation wavelengths.

LLC growth dynamics in young male C57Bl/6N mice treated with Photolon, and vehicle groups following the PDT. For all experimental groups irradiation was performed 1 hour after Photolon treatment at 14th day after tumor inoculation using the semiconductor laser “Lika-Khirurg M” (Fotonika Plus, Ukraine), and the following parameter settings: l=660 nm, P=250 mW/cm2, light dose = 225 J/cm2. Irradiation regime was controlled by Nova II Laser Power Meter (Ophir Optronics, Israel).

Orthotopicaly inoculated DU4475 growth dynamic in SCID/beige and CD1-Foxn1nu 6-7 weeks old females. 2×10*6 Cells in 100 μl (50 μl RPMI+50 μl Matrigel)

Deliverable

A detailed study report including description of study design, experimental data and interpretation, preliminary statistics, requested tissue samples and terminal blood.

Sample Submission:

Dry compound or compound in pre-made dosing formulation (amount required depends on the dosing levels and schedules). For example, for treating a group of 8 mice at 10 mg/kg, twice daily (b.i.d.) for 1 week, about 16 mg of the test compound is required.